2024 Regular SessionFlorida Legislature

H1431: International Drug Reference Pricing

Legislative Summary

Requires prescription drug manufacturer permitholders to annually report certain international price data to AHCA; provides for administrative enforcement via specified fine & permit suspension; requires AHCA to contract with entity to designate reference price source countries & establish reference prices for prescription drugs based on certain criteria; requires agency contractor to weigh reference price benchmark value of such countries in two or more tiers, using specified criteria; requires agency contractor to analyze specified data to compare prices among source countries using specified exchange rate source; requires agency contractor to establish reference price for prescribed drugs or products; requires agency contractor to provide reference prices by specified date each year; requires AHCA to publish prices online within specified time; requires pharmacies to charge no more than reference price for cash-paying patients; requires certain health insurers to provide reimbursement for certain prescription drugs no higher than reference price; requires health insurers to use certain savings to offset certain payer costs; requires each health insurer to document anticipated savings & premium reductions in rate filings following availability of reference prices; requires each health insurer to assess actuarial effect of reference pricing program for each insurer product for each plan year; requires each health insurer to submit annual report on assessed effect of such program to OIR or AHCA; requires OIR & AHCA to submit joint report to Governor & Legislature; requires every health maintenance organization to comply with provisions of specified section.

Demographic Impact

Overall analysis of equity impact

80% Positive
High ConfidenceView detailed demographic breakdown ↓

Unlock Full Demographic Insights

Go beyond the overall score.

Gain a deeper understanding of this bill's potential impact across diverse communities, including detailed breakdowns by category and subgroup. Access to this granular analysis helps ensure equitable outcomes.

Enable full analysis features for your organization.

Contact Sales to Learn More

Or email us directly at sales@legiequity.us.

Bill History

1/6/2024
Filed
House of Representatives
1/9/2024
1st Reading (Original Filed Version)
House of Representatives
1/13/2024
Referred to Select Committee on Health Innovation
House of Representatives
1/13/2024
Referred to Appropriations Committee
House of Representatives
1/13/2024
Referred to Health & Human Services Committee
House of Representatives
1/13/2024
Now in Select Committee on Health Innovation
House of Representatives
1/18/2024
Added to Select Committee on Health Innovation agenda
House of Representatives
1/22/2024
Favorable by Select Committee on Health Innovation
House of Representatives
1/23/2024
Reported out of Select Committee on Health Innovation
House of Representatives
1/23/2024
Now in Appropriations Committee
House of Representatives
3/8/2024
Died in Appropriations Committee
House of Representatives

Roll Call Votes

House Select Committee on Health Innovation
1/22/2024
13
Yea
2
Nay
0
Not Voting
1
Absent
Result: PASSED

Status Information

Current Status
Failed(3/8/2024)
Chamber
House of Representatives
Sine DiePrior Session

Sponsors

Republican: 2

Primary Sponsor

Randy Fine
Randy Fine
Republican

Documents

Introduced
Bill Text1/6/2024117.8 KB
Veto Letter
Veto Letter1/23/2024728.5 KB
Veto Letter
Veto Letter1/21/2024728.5 KB